Influenza Vaccine Comparisons
|INFLUENZA VACCINE COMPARISONS|
|Storage and Handling|
• Store refrigerated at 2–8°C (36–46°F)
• Do not freeze; discard if product has been frozen
• Protect from light
• Do not use influenza vaccine beyond the expiration
• Once the stopper of the multi-dose vial has been
|Inactivated Influenza Vaccine, Trivalent (IIV3), Standard Dose|
|Afluria||≥9yrs1,2||IM||egg protein, neomycin, polymyxin||0||0.5mL single-dose prefilled syringe|
|24.5||5mL multi-dose vial|
|Fluvirin||≥4yrs||IM||egg protein, latex||≤1||0.5mL single-dose prefilled syringe|
|egg protein, polymyxin, neomycin||25||5mL multi-dose vial|
|Fluzone||≥6mos||IM||egg protein, gelatin||25||5mL multi-dose vial|
|Inactivated Influenza Vaccine, Trivalent (IIV3), High Dose|
|≥65yrs||IM||egg protein||0||0.5mL single-dose prefilled syringe|
|Inactivated Influenza Vaccine, Quadrivalent (IIV4), Standard Dose|
|≥3yrs||IM||egg protein||0||0.5mL single-dose prefilled syringe|
|≥3yrs||IM||egg protein||<25||5mL multi-dose vial|
|6–35mos||IM||egg protein||0||0.25mL single-dose prefilled syringe|
|≥6mos||25||5mL multi-dose vial|
|≥36mos||0||0.5mL single-dose prefilled syringe, 0.5 mL single-dose vial|
|18–64yrs||ID||egg protein||0||0.1mL single-dose prefilled microinjection system|
|Inactivated Influenza Vaccine, Cell-Culture-Based (ccIIV3)|
|Flucelvax||≥18yrs||IM||egg protein, latex||0||0.5mL single-dose prefilled syringe|
|Recombinant Influenza Vaccine, Trivalent (RIV3)|
|FluBlok||≥18yrs||IM||0||0.5mL single-dose vial|
|Live-attenuated Influenza Vaccine, Quadrivalent (LAIV4)|
|2–49yrs||IN||egg protein, gentamicin, gelatin, arginine||0||0.2mL single-dose prefilled nasal spray|
Key: IM = intramuscular; ID = intradermal; IN = intranasal
IM: For adults and older children, the recommended site of IM administration is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Specific guidance regarding site and needle length for intramuscular administration can be found in ACIP's General Recommendations on Immunization.
1Age indication per package insert is ≥5yrs; however, the ACIP recommends Afluria not be used in children aged 6mos–8yrs because of increased risk of febrile reactions noted in this age group with CSL's 2010 Southern Hemisphere TIV. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child aged 5–8yrs who has a medical condition that increases the child's risk for influenza complications, Afluria can be used; however, providers should discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria before administering this vaccine. Afluria may be used in persons aged ≥9yrs.
2Aged 18−64yrs for jet injector use.
3Should not be used in persons aged <2yrs or >49yrs, children aged 2−17yrs receiving aspirin or aspirin-containing products, pregnant women, immunocompromised persons, children aged 2−4yrs with asthma or had wheezing episode within past 12mos, and persons who received influenza antivirals within previous 48hrs.
Immunization providers should review FDA-approved prescribing information for 2015–2016 influenza vaccines for the most updated information, including (but not limited to) indications, contraindications, and precautions. Table listing reflects vaccines expected to be available during the 2015–2016 influenza season. This information is subject to change. For information on individual vaccines, see the product entries, contact the manufacturer, or call the National Immunization Hotline at (800) 232-4636.
From: Interim Recommendations: Prevention and Control of Influenza with Vaccines: Recommendations of ACIP, United States, 2015−16 Influenza Season.